Actuate Therapeutics Intends To Initiate Phase 1/2 Clinical Program To Evaluate Oral Tablet Dosage Form Of Elraglusib In Patients With Advanced Cancer

Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer.

The phase 1 portion of the planned Phase 1/2 program aims to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and dose-limiting toxicities (DLTs) of elraglusib tablets administered once daily and will investigate the pharmacokinetics (PK) of elraglusib tablets as well as the preliminary anti-tumor activity of elraglusib when administered as tablets. The goal of the phase 1 portion of the program will be to establish the recommended dose(s) of elraglusib tablets for expansion (RDE) in subsequent development